North America Digital Dose Inhaler Market Size, Share & Industry Trends Analysis Report By Product (Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI)), By Type, By Indication (COPD, Asthma, and Others), By Country and Growth Forecast, 2023 - 2030
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Digital Dose Inhaler Market
Market Report Description
The North America Digital Dose Inhaler Market would witness market growth of 19.0% CAGR during the forecast period (2023-2030).
The market is anticipated to be significantly driven by factors such as the increasing geriatric population, the growth of both severe and mild respiratory disorders, the increasing demand for these new generation inhalation devices, the rising need for cost-effective medications, the growing awareness among people about the benefits of generic drugs, etc. Opportunities for the market include increasing investment in research and development, advancing asthma device manufacturing, and providing cost-effective medication for patients.
Government initiatives, including Medicare and Medicaid plans, group association policies, employee policies, and individual insurance policies, influence the market. In addition, the development of connectivity technologies to improve patient medication compliance and assure the administration of the correct dosage and the introduction of new products create lucrative opportunities market actors.
In the United States, millions of individuals suffer from respiratory disease. Over 25 million individuals have asthma. Strategies to reduce environmental triggers, ensure individuals receive the correct medications, and prevent asthma-related hospitalizations. More than 16 million individuals in the United States have COPD (chronic obstructive pulmonary disease), a leading cause of mortality. Strategies to prevent the disease, such as reducing air pollution and assisting smokers to cease, can be crucial for lowering COPD-related fatalities. Also beneficial for the prevention and treatment of other respiratory diseases are interventions tailored to high-risk populations. Asthma and other respiratory diseases are on the rise, increasing the demand for bronchodilators and driving market growth in North America.
The US market dominated the North America Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $14,618.3 million by 2030. The Canada market is experiencing a CAGR of 21.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 20.6% during (2023 - 2030).
Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Digital Dose Inhaler Market is Projected to reach USD 49 Billion by 2030, at a CAGR of 19.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Metered Dose Inhaler (MDI)
- Dry Powder Inhaler (DPI)
By Type
- Branded Medication
- Generic Medication
By Indication
- COPD
- Asthma
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Sensirion AG
- Teva Pharmaceuticals Industries Ltd.
- OPKO Health, Inc.
- Propeller Health (ResMed, Inc.)
- Novartis AG
- AstraZeneca PLC
- Glenmark Pharmaceuticals Limited
- Beximco Pharmaceuticals Ltd.
- GlaxoSmithKline PLC
- Mundipharma Deutschland GmbH & Co. KG
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Related Reports: